TX-PLANVIEW
5.7.2022 15:05:08 CEST | Business Wire | Press release
Planview , a global leader in Portfolio Management and Work Management solutions, today announced it has completed its acquisition of Tasktop, initially announced on May 18 .
“Bringing Mik Kersten and the Tasktop team into Planview will help deliver new levels of excellence to companies and industries navigating through change,” said Razat Gaurav, CEO of Planview. “By merging Tasktop’s institutional expertise in scaling software with Planview’s focus on delivering enterprise-scale visibility, we’ve created a new industry powerhouse poised to help organizations connect the business of software delivery and conduct their business transformations with unprecedented confidence and efficiency.”
The combination of Planview and Tasktop means customers work with a single, comprehensive organization with cutting-edge expertise in capabilities ranging from Value Stream Management (VSM) to Strategic Portfolio Management and Enterprise Agile Planning, among others. At a time when organizations are navigating business transformations amid a turbulent macroeconomic landscape, having a single partner that provides intelligence and visibility into the progress of those transformations helps ensure success.
According to a May 2022 Forrester blog, The Market For VSM And SPM Takes A Big Step Forward , “We see the Planview + Tasktop combination having the potential to shake up the (Strategic Portfolio Management) SPM and VSM marketplace and force it to evolve at an even faster pace by putting pressure on existing leaders in agile planning and DevOps management solutions.”
“To succeed with digital transformation, organizations must expand beyond Agile teams to portfolio-level business agility,” said Dean Leffingwell, creator of SAFe® and cofounder, Scaled Agile, Inc. “We’re headed in the right direction. With so many enterprises now deploying SAFe, and the shift from project to product described in Mik Kersten’s book gaining mind share, this new way of working and thinking is finding its way into the CEO’s office. This new paradigm is helping leaders effectively connect the strategic portfolio level with software delivery, which introduces huge opportunities for the business. It is great to see our Scaled Agile partners Planview and Tasktop coming together to help enterprises maximize and accelerate those opportunities.”
The newly combined entity affirms Planview’s leading position globally with 4,500 enterprise customers worldwide, more than 1,300 employees, and a combined FY21 revenue of approximately $400 million. Planview will continue to invest in and support the Tasktop product lines as standalone solutions in the immediate term and will evaluate product direction long term based on customer and industry feedback. As part of the transaction, Tasktop cofounder and CEO, Mik Kersten, has joined Planview as Chief Technology Officer. You can read more about the Tasktop team’s go-forward focus in Mik’s blog .
Sumeru Equity Partners , Tasktop’s lead investor, along with minority investors Elsewhere Partners and Yaletown Partners, and Tasktop’s management will be rolling part of their equity in the new combined entity and will maintain minority interest in Planview alongside its majority shareholders, TPG and TA Associates. Golub Capital provided committed debt financing and Jefferies LLC acted as financial advisors to Planview. Ropes & Gray served as legal counsel to Planview. AGC Partners acted as financial advisors to Tasktop / Sumeru Equity Partners, and Kirkland & Ellis served as legal counsel.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions create an organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005348/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
Andersen Consulting får ny samarbejdspartner i Usbekistan22.10.2026 21:34:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for cybersikkerhed og forretningstransformation gennem en samarbejdsaftale med Algoruni, et konsulentfirma med base i Usbekistan. Algoruni rådgiver organisationer om at opbygge cyberrobusthed og håndtere bredere prioriteter inden for ledelse, regulering og bæredygtighed. Virksomheden har base i Tasjkent og tilbyder tjenester inden for cybersikkerhedsstrategi og databeskyttelse, virksomhedsledelse og driftsforbedringer samt ESG-strategi og -rapportering. Fokus er på praktiske løsninger, der er tilpasset den enkelte kundes situation. "Enhver organisation står over for en unik kombination af risici og muligheder. Derfor mener vi, at effektive løsninger skal tage udgangspunkt i virksomhedens konkrete situation," udtalte Alisher Zaynutdinov, administrerende direktør for Algoruni. "Som samarbejdsvirksomhed med Andersen Consulting kan vi kombinere denne tilgang med et bredere netværk af internationale ressourcer og perspektiver, så vi får nye
Andersen Global udvider sine juridiske kompetencer i Argentina gennem samarbejde med MHR22.10.2026 20:20:00 CEST | Pressemeddelelse
Andersen Global styrker sine juridiske kompetencer i Argentina gennem en samarbejdsaftale med Martínez de Hoz & Rueda (MHR) efter integrationen af teamet fra MBP Partners i firmaet. MBP Partners var tidligere et samarbejdsfirma i Andersen Global og arbejdede sammen med organisationens medlemsfirmaer og samarbejdsfirmaer for at bistå klienter med både lokale og internationale forhold. Med integrationen af MBP Partners viderefører den nye samarbejdsaftale mellem Andersen Global og MHR det eksisterende samarbejde og styrker samtidig Andersen Globals juridiske kompetencer i Argentina. MHR er et fullservice advokatfirma, der rådgiver klienter inden for olie og gas, selskabsretlige og finansielle forhold, energi, minedrift, fintech, infrastruktur, teknologi og andre centrale sektorer. Firmaet bistår danske og internationale virksomheder, finansielle institutioner, investeringsfonde, fintechvirksomheder og andre organisationer med komplekse transaktioner, regulatoriske spørgsmål og strategisk
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press release
For Trade and Medical Media Only Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
